A retrospective comparison of docetaxel and paclitaxel for patients with advanced or recurrent esophageal cancer who previously received platinum-based chemotherapy

Oncology

Volumn 81, Issue 3-4, 2011, Pages 237-242

  Mizota, Ayako ^a   Shitara, Kohei ^a   Kondo, Chihiro ^a   Nomura, Motoo ^a   Yokota, Tomoya ^a   Takahari, Daisuke ^a   Ura, Takashi ^a   Muro, Kei ^a  

^a AICHI CANCER CENTER HOSPITAL   (Japan)

Author keywords

Docetaxel; Esophageal cancer; Paclitaxel

Indexed keywords

CIMETIDINE; DEXAMETHASONE; DIPHENHYDRAMINE; DOCETAXEL; PACLITAXEL; PLATINUM;

ACUTE HEART FAILURE; ACUTE LIVER FAILURE; ADULT; ADVANCED CANCER; AGED; ALLERGIC REACTION; ARTICLE; CANCER PATIENT; CANCER SURVIVAL; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ESOPHAGUS CANCER; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECURRENT CANCER; RETROSPECTIVE STUDY; SENSORY NEUROPATHY; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; ESOPHAGEAL NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; PACLITAXEL; RETROSPECTIVE STUDIES; TAXOIDS;

EID: 81155125099     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000334057     Document Type: Article

References (16)

1. International Agency for Research on Cancer; GLOBOCAN 2008. http://www-dep. iarc.fr/CancerMondial.htm.
2. Blot WJ, McLaughlin JK: The changing epidemiology of esophageal cancer. Semin Oncol 1999; 26: 2-8.
3. Devesa SS, Blot WJ, Fraumeni JF Jr: Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 1998; 83: 2049-2053.
4. Vizcaino AP, Moreno V, Lambert R, Parkin DM: Time trends incidence of both major histologic types of esophageal carcinomas in selected countries, 1973-1995. Int J Cancer 2002; 99: 860-868.
5. Shibata A, Matsuda T, Ajiki W, Sobue T: Trend in incidence of adenocarcinoma of the esophagus in Japan, 1993-2001. Jpn J Clin Oncol 2008; 38: 464-468.
6. Iizuka T, Kakegawa T, Ide H, Ando N, Watanabe H, Tanaka O, Takagi I, Isono K, Ishida K, Arimori M: Phase II evaluation of cisplatin and 5-fluorouracil in advanced squamous cell carcinoma of the esophagus: A Japanese Esophageal Oncology Group Trial. Jpn J Clin Oncol 1992; 22: 172-176.
7. Hayashi K, Ando N, Watanabe H, Ide H, Nagai K, Aoyama N, Takiyama W, Ishida K, Isono K, Makuuchi H, Imamura M, Shinoda M, Ikeuchi S, Kabuto T, Yamana H, Fukuda H: Phase II evaluation of protracted infusion of cisplatin and 5-fluorouracil in advanced squamous cell carcinoma of the esophagus: A Japan Esophageal Oncology Group (JEOG) Trial (JCOG9407). Jpn J Clin Oncol 2001; 31: 419-423.
8. Gong Y, Ren L, Zhou L, Zhu J, Huang M, Zhou X, Wang J, Lu Y, Hou M, Wei Y: Phase II evaluation of nedaplatin and paclitaxel in patients with metastatic esophageal carcinomas. Cancer Chemother Pharmacol 2009; 64: 327-333.
9. El Rayes BF, Shields A, Zalupski M, Heilbrun LK, Jain V, Terry D, Ferris A, Philip PA: A phase II study of carboplatin and paclitaxel in esophageal cancer. Ann Oncol 2004; 15: 960-965.
10. Ilson DH, Ajani J, Bhalla K, Forastiere A, Huang Y, Patel P, Martin L, Donegan J, Pazdur R, Reed C, Kelsen DP: Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagus. J Clin Oncol 1998; 16: 1826-1834.
11. Lin CC, Hsu CH, Cheng JC, Wang HP, Lee JM, Yeh KH, Yang CH, Lin JT, Cheng AL, Lee YC: Concurrent chemoradiotherapy with twice weekly paclitaxel and cisplatin followed by esophagectomy for locally advanced esophageal cancer. Ann Oncol 2007; 18: 93-98.
12. Muro K, Hamaguchi T, Ohtsu A, Boku N, Chin K, Hyodo I, Fujita H, Takiyama W, Ohtsu T: Phase II study of single-agent docetaxel in patients with metastatic esophageal cancer. Ann of Oncol 2004; 15: 955-959.
13. Kato K, Tahara M, Hironaka S, Muro K, Takiuchi H, Hamamoto Y, Imamoto H, Amano N, Seriu T: A phase II study of paclitaxel by weekly 1-h infusion for advanced or recurrent esophageal cancer in patients who had previously received platinum-based chemotherapy. Cancer Chemother Pharmacol 2010; 67: 1265-1272.
14. Hironaka S, Zenda S, Boku N: Weekly paclitaxel as second-line chemotherapy for advanced or recurrent gastric cancer. Gastric Cancer 2006; 9: 14-18.
15. Kodera Y, Ito S, Mochizuki Y: A phase II study of weekly paclitaxel as second-line chemotherapy for advanced gastric cancer (CCOG0302 study). Anticancer Res 2007; 27: 2667-2671.
16. Horiguchi J, Rai Y, Tamura K, Taki T, Hisamatsu K, Ito Y, Seriu T, Tajima T: Phase II study of weekly paclitaxel for advanced or metastatic breast cancer in Japan. Anticancer Res 2009; 29: 625-630.